Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-26T09:48:30.844Z Has data issue: false hasContentIssue false

Chapter 20 - Contraception in Women with Cancer

from Section 2A - Sexual and Reproductive Healthcare: Contraception

Published online by Cambridge University Press:  16 January 2024

By
Anne Gompel
Edited by
Johannes Bitzer  and
Tahir A. Mahmood
Johannes Bitzer
Affiliation:
University Women's Hospital, Basel
Tahir A. Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Get access

Summary

Cancer, although more frequent after menopause, can reach younger and fertile patients or occur during childhood. Contraception in women during the treatment of or after cancer is an important subject and too often neglected. Studies show that counseling on contraception in women with cancer is often missing [1].

Type
Chapter
Information
Textbook of Contraception, Sexual and Reproductive Health , pp. 140 - 145
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dominick, SA, McLean, MR, Whitcomb, BW et al. Contraceptive practices among female cancer survivors of reproductive age. Obstet Gynecol. 2015;126(3):498–507.CrossRefGoogle ScholarPubMed
Hadnott, TN, Stark, SS, Medica, A et al. Perceived infertility and contraceptive use in the female, reproductive-age cancer survivor. Fertil Steril. 2019;111(4):763–71.CrossRefGoogle ScholarPubMed
Plu-Bureau, G, Maitrot-Mantelet, L, Hugon-Rodin, J, Canonico, M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Pract Res Clin Endocrinol Metab. 2013;27(1):25–34.CrossRefGoogle ScholarPubMed
Chelmow, D, Pearlman, MD, Young, A et al. Executive summary of the Early-Onset BC Evidence Review Conference. Obstet Gynecol. 2020;135(6):1457–78.CrossRefGoogle Scholar
Thavendiranathan, P, Nolan, MT. An emerging epidemic: Cancer and heart failure. Clin Sci (Lond). 2017;131(2):113–21.CrossRefGoogle ScholarPubMed
Taylor, C, Correa, C, Duane, FK et al. Estimating the risks of BC radiotherapy: Evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9.CrossRefGoogle Scholar
Heer, E, Harper, A, Escandor, N et al. Global burden and trends in premenopausal and postmenopausal BC: A population-based study. Lancet Glob Health. 2020;8(8):e1027–37.CrossRefGoogle Scholar
Parisi, F, Razeti, MG, Blondeaux, E et al. Current state of the art in the adjuvant systemic treatment of premenopausal patients with early BC. Clin Med Insights Oncol. 2020;14:1179554920931816.CrossRefGoogle Scholar
Sofiyeva, N, Siepmann, T, Barlinn, K, Seli, E, Ata, B. Gonadotropin-releasing hormone analogs for gonadal protection during gonadotoxic chemotherapy: A systematic review and meta-analysis. Reprod Sci. 2019;26(7):939–53.CrossRefGoogle ScholarPubMed
Gompel, A, Ramirez, I, Bitzer, J, European Society of Contraception Expert Group on Hormonal Contraception. Contraception in cancer survivors: An expert review Part I. Breast and gynaecological cancers.Eur J Contracept Reprod Health Care. 2019;24(3):167–74.CrossRefGoogle ScholarPubMed
Valachis, A, Tsali, L, Pesce, LL et al. Safety of pregnancy after primary breast carcinoma in young women: A meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv. 2010;65(12):786–93.CrossRefGoogle ScholarPubMed
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015. www.who.int/publications/i/item/9789241549158.Google Scholar
Dominick, S, Hickey, M, Chin, J, Su, HI. Levonorgestrel intrauterine system for endometrial protection in women with BC on adjuvant tamoxifen. Cochrane Database Syst Rev. 2015;12:CD007245.CrossRefGoogle Scholar
Kotsopoulos, J, Lubinski, J, Moller, P et al. Timing of oral contraceptive use and the risk of BC in BRCA1 mutation carriers. BC Res Treat. 2014;143(3):579–86.Google Scholar
Endometrial cancer statistics [Internet]. World Cancer Research Fund. 2018. https://bit.ly/3HmkBJI.Google Scholar
Dominguez-Valentin, M, Sampson, JR, Seppälä, TT et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15–25.CrossRefGoogle ScholarPubMed
Baker, J, Obermair, A, Gebski, V, Janda, M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.CrossRefGoogle ScholarPubMed
Koskas, M, Azria, E, Walker, F et al. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res. 2012;32(3):1037–43.Google ScholarPubMed
Bray, F, Ferlay, J, Soerjomataram, I et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.Google ScholarPubMed
Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use.: 2.Google Scholar
Rousset-Jablonski, C, Selle, F, Adda-Herzog, E et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: Guidelines from the French national network dedicated to rare gynaecological cancers. Eur J Cancer. 2019;116:35–44.CrossRefGoogle ScholarPubMed
Syngal, S, Brand, RE, Church, JM et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62.CrossRefGoogle ScholarPubMed
Cagnacci, A, Ramirez, I, Bitzer, J, Gompel, A. Contraception in cancer survivors: An expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. Eur J Contracept Reprod Health Care. 2019;24(4):299–304.CrossRefGoogle ScholarPubMed
Dashti, SG, Chau, R, Ouakrim, DA et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA. 2015;314(1):61–71.CrossRefGoogle ScholarPubMed
Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. 4th edition. Geneva: World Health Organization, 2010. (WHO Guidelines Approved by the Guidelines Review Committee.) www.ncbi.nlm.nih.gov/books/NBK138639.Google Scholar
Hodgkin lymphoma incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/incidence.Google Scholar
Non-Hodgkin lymphoma incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphoma/incidence.Google Scholar
Leukaemia (all subtypes combined) incidence statistics. Cancer Research UK. 2015. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia/incidence.Google Scholar
Meirow, D, Rabinovici, J, Katz, D et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer. 2006;107(7):1634–41.CrossRefGoogle ScholarPubMed
Bates, JS, Buie, LW, Woodis, CB. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy. 2011;31(11):1092–1110.CrossRefGoogle ScholarPubMed
Kane, EV, Roman, E, Becker, N et al. Menstrual and reproductive factors, and hormonal contraception use: Associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. Ann Oncol. 2012;23(9):2362–74.CrossRefGoogle Scholar
Iversen, L, Sivasubramaniam, S, Lee, AJ, Fielding, S, Hannaford, PC. Lifetime cancer risk and combined oral contraceptives: The Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9.CrossRefGoogle ScholarPubMed
Stapelfeld, C, Dammann, C, Maser, E. Sex-specificity in lung cancer risk. Int J Cancer. 2020;146(9):2376–82.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×